Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 6/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD5 | P21918 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13383619 | 0.88 | HRH1 (0.45) | HRH3LTA4HHRH1DRD1DRD4 | |
| SCHEMBL12266409 | 0.86 | HRH3 (0.49) | HRH3LTA4HHRH1DRD1DRD4 | |
| SCHEMBL12271044 | 0.81 | CYP1A2 (0.55) | LTA4HHRH1DRD1DRD4DRD5 | |
| SCHEMBL12266420 | 0.78 | KDM4E (0.55) | HRH3LTA4HHRH1DRD1DRD4 | |
| SCHEMBL12266379 | 0.77 | SMN1; SMN2 (0.50) | HRH3HRH1DRD3DRD2PSMB1 | |
| SCHEMBL12271077 | 0.74 | MEN1 (0.48) | HRH3HRH1KDM4ESMN1; SMN2 | |
| SCHEMBL13383615 | 0.74 | CHRM3 (0.51) | — | |
| SCHEMBL224627 | 0.72 | HRH3 (0.85) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL227588 | 0.72 | HRH3 (0.85) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL8973201 | 0.70 | HRH3 (0.82) | HRH3LTA4HPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | HRH3 143/4885LTA4H 4660/4885HRH1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.